Microbot Medical (NASDAQ:MBOT) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why

Posted by Geri Gentry on Apr 3rd, 2025

Microbot Medical Inc. (NASDAQ:MBOT – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.33 and traded as high as $1.53. Microbot Medical shares last traded at $1.49, with a volume of 374,393 shares traded.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price objective on shares of Microbot Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, January 24th.

Check Out Our Latest Report on Microbot Medical

Microbot Medical Stock Down 7.6 %

The stock has a market capitalization of $54.55 million, a price-to-earnings ratio of -1.96 and a beta of 1.60. The stock’s 50-day simple moving average is $1.72 and its 200 day simple moving average is $1.33.

Microbot Medical (NASDAQ:MBOT – Get Free Report) last announced its earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). As a group, equities research analysts anticipate that Microbot Medical Inc. will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Microbot Medical stock. Renaissance Technologies LLC acquired a new position in shares of Microbot Medical Inc. (NASDAQ:MBOT – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 105,658 shares of the biotechnology company’s stock, valued at approximately $118,000. Renaissance Technologies LLC owned 0.52% of Microbot Medical as of its most recent SEC filing. Institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

(Get Free Report)

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.